Article Text

other Versions

PDF
FPL-vaccinated cats are protected from CPV2c and CPV2b challenge
  1. S. C. Jack,
  2. D. Sutton,
  3. A. Bhogle,
  4. N. Spibey and
  5. M. Francis
  1. MSD Animal Health, Walton Manor, Walton, Milton Keynes, Buckinghamshire MK7 7AJ, UK;
  1. E-mail for correspondence: samantha.jack{at}merck.com

Statistics from Altmetric.com

Phylogenetic analysis of canine parvovirus type 2 (CPV2) strongly suggests that it is a virus variant of Feline panleukopenia virus (FPLV), or a closely related virus, that may have arisen via an intermediate host (Truyen and others 1998). CPV2 was originally isolated from dogs in the 1970s and reported not to infect cats. Since then new variants have evolved, CPV2a, CPV2b and, more recently, CPV2c (Parrish and others 1991, Buonavoglia and others 2001). These newer variants have the ability to infect cats and, in some cases, cause FPL-like clinical signs. All variants have been isolated from the faeces of infected cats (Decaro and others 2010).

Recently, CPV variants have been shown to be prevalent in faeces from shelter cats and dogs (Clegg and others 2012). While at least one FPLV vaccine has been shown to be efficacious against CPV2b infection in cats (Chalmers and others 1999), no studies on the ability of vaccines to protect cats against the most recent CPV2c isolates have yet been reported. Here, we show that vaccination with live attenuated FPL MW-1 strain, a component of Nobivac …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.